bioMérieux revenue and financials
€81.45Change from previous close: +1.69%Absolute change: +€1.35
In the fiscal year ended December 2025, bioMérieux reported revenue of €4.07B (+2.26% year over year). Net income was €397.5M, a net margin of 9.8%.
Fiscal year ending in December. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +2.26%
- 2025 vs 2024
- Net income growth
- −8.03%
- 2025 vs 2024
- Net margin
- 9.8%
- 2024: 10.9%
Financial data
Amounts in millions of EUR; per-share values in EUR; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total revenue | 4,070 | 3,980 | 3,675 | 3,589 | — |
| Cost of revenue | 1,761 | 1,765 | 1,617 | 1,580 | — |
| Gross profit | 2,309 | 2,215 | 2,057 | 2,009 | — |
| Selling, general and administrative | 1,111 | 1,098 | 1,021 | 955 | — |
| Research and development | 507 | 492 | 460 | 447 | — |
| Operating income | 695 | 638 | 569 | 626 | — |
| EBIT | 542 | 595 | 453 | 585 | — |
| EBITDA | 849 | 898 | 712 | 833 | — |
| Interest expense | 15.8 | 16.0 | 15.8 | 4.1 | — |
| Pre-tax income | 526 | 579 | 438 | 581 | — |
| Income tax | 129 | 154 | 115 | 140 | — |
| Net income | 398 | 432 | 358 | 452 | — |
| Net income to common shareholders | 398 | 432 | 358 | 452 | — |
| Basic EPS | 3.37 | 3.67 | 3.03 | 3.84 | — |
| Diluted EPS | 3.34 | 3.64 | 3.01 | 3.82 | — |
| Average shares (basic) | 118 | 118 | 118 | 118 | — |
| Average shares (diluted) | 119 | 119 | 119 | 118 | — |